BR112018067479A2 - anticorpo, fragmento de ligação ao antígeno de um anticorpo, molécula quimérica, receptor de antígeno quimérico, polinucleotídeo, célula, métodos para preparação de receptor de antígeno quimérico, para fabricação de um anticorpo e para determinação da presença de células cd127+, composição farmacêutica, meio terapêutico de combinação, método de diagnóstico, e, uso de um anticorpo anti-cd127 ou um fragmento de ligação ao antígeno do mesmo - Google Patents
anticorpo, fragmento de ligação ao antígeno de um anticorpo, molécula quimérica, receptor de antígeno quimérico, polinucleotídeo, célula, métodos para preparação de receptor de antígeno quimérico, para fabricação de um anticorpo e para determinação da presença de células cd127+, composição farmacêutica, meio terapêutico de combinação, método de diagnóstico, e, uso de um anticorpo anti-cd127 ou um fragmento de ligação ao antígeno do mesmoInfo
- Publication number
- BR112018067479A2 BR112018067479A2 BR112018067479A BR112018067479A BR112018067479A2 BR 112018067479 A2 BR112018067479 A2 BR 112018067479A2 BR 112018067479 A BR112018067479 A BR 112018067479A BR 112018067479 A BR112018067479 A BR 112018067479A BR 112018067479 A2 BR112018067479 A2 BR 112018067479A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- binding fragment
- antigen
- chimeric
- antigen receptor
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title 2
- 239000000427 antigen Substances 0.000 title 2
- 102000036639 antigens Human genes 0.000 title 2
- 108091007433 antigens Proteins 0.000 title 2
- 239000012634 fragment Substances 0.000 title 2
- 238000002648 combination therapy Methods 0.000 title 1
- 238000002405 diagnostic procedure Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000040430 polynucleotide Human genes 0.000 title 1
- 108091033319 polynucleotide Proteins 0.000 title 1
- 239000002157 polynucleotide Substances 0.000 title 1
- 102000010782 Interleukin-7 Receptors Human genes 0.000 abstract 3
- 108010038498 Interleukin-7 Receptors Proteins 0.000 abstract 3
- 102000000704 Interleukin-7 Human genes 0.000 abstract 1
- 108010002586 Interleukin-7 Proteins 0.000 abstract 1
- 101100371162 Mus musculus Tslp gene Proteins 0.000 abstract 1
- 230000001270 agonistic effect Effects 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 229940100994 interleukin-7 Drugs 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
a invenção se refere aos anticorpos humanizados direcionados contra o domínio extracelular da cadeia alfa do receptor para interleucina 7 (il-7), especialmente contra o receptor para il-7 de humano expresso em células humanas (também denominado 7ralfa de humano ou il-7ra ou cd127) e que não interfere com as vias de sinalização de il-7 ou tslp. os anticorpos da invenção não apresentam efeito antagonista no receptor de il-7, mas ainda podem apresentar atividade citotóxica contra células positivas para cd127. em uma modalidade particular, o anticorpo não apresenta efeito agonista no receptor de il-7.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662301271P | 2016-02-29 | 2016-02-29 | |
| PCT/IB2017/000293 WO2017149394A1 (en) | 2016-02-29 | 2017-02-28 | Non-antagonistic antibodies directed against the alpha chain of the il7 receptor extracellular domain and use thereof in cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018067479A2 true BR112018067479A2 (pt) | 2019-01-15 |
Family
ID=58530580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018067479A BR112018067479A2 (pt) | 2016-02-29 | 2017-02-28 | anticorpo, fragmento de ligação ao antígeno de um anticorpo, molécula quimérica, receptor de antígeno quimérico, polinucleotídeo, célula, métodos para preparação de receptor de antígeno quimérico, para fabricação de um anticorpo e para determinação da presença de células cd127+, composição farmacêutica, meio terapêutico de combinação, método de diagnóstico, e, uso de um anticorpo anti-cd127 ou um fragmento de ligação ao antígeno do mesmo |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11230602B2 (pt) |
| EP (1) | EP3423496B1 (pt) |
| JP (1) | JP7053479B2 (pt) |
| KR (1) | KR20180118746A (pt) |
| CN (1) | CN109195987B (pt) |
| AU (1) | AU2017225495B2 (pt) |
| BR (1) | BR112018067479A2 (pt) |
| CA (1) | CA3014313A1 (pt) |
| CY (1) | CY1122072T1 (pt) |
| DK (1) | DK3423496T3 (pt) |
| ES (1) | ES2737307T3 (pt) |
| HR (1) | HRP20191445T1 (pt) |
| HU (1) | HUE045183T2 (pt) |
| IL (1) | IL261330B2 (pt) |
| LT (1) | LT3423496T (pt) |
| MA (1) | MA43767B1 (pt) |
| MD (1) | MD3423496T2 (pt) |
| ME (1) | ME03446B (pt) |
| PL (1) | PL3423496T3 (pt) |
| PT (1) | PT3423496T (pt) |
| RS (1) | RS59223B1 (pt) |
| SI (1) | SI3423496T1 (pt) |
| WO (1) | WO2017149394A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2955196A1 (en) | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
| EP3676292A1 (en) * | 2017-08-29 | 2020-07-08 | OSE Immunotherapeutics | Method and preparation for sorting out t effector cells using anti-cd127 antibodies for applications in cell therapy |
| JP7530638B2 (ja) * | 2018-05-10 | 2024-08-08 | ニューラクル サイエンス カンパニー リミテッド | 配列類似性１９、メンバーａ５抗体を有する抗ファミリー及びその使用方法 |
| US20220273713A1 (en) * | 2019-06-28 | 2022-09-01 | The University Of Melbourne | Method of inhibiting or activating gamma delta t cells |
| CN110894237B (zh) * | 2019-12-05 | 2021-08-03 | 山东省分析测试中心 | 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用 |
| EP4142777A4 (en) * | 2020-04-27 | 2024-06-12 | Memorial Sloan-Kettering Cancer Center | CHIMERIC ANTIGEN RECEPTORS DIRECTED TO CD127 AND USE THEREOF |
| WO2021236691A1 (en) * | 2020-05-18 | 2021-11-25 | Jumaa Weinacht Hassan | Composition for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia |
| CN113501878B (zh) * | 2021-02-03 | 2022-12-02 | 北京智仁美博生物科技有限公司 | 针对人tslp的多种抗体及其用途 |
| US20220389104A1 (en) * | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| CA2655392A1 (en) | 2006-05-31 | 2007-12-06 | The Regents Of The University Of California | Cd127 expression inversely correlates with foxp3 and suppressive function of cd4+ tregs |
| ATE542830T1 (de) | 2006-12-04 | 2012-02-15 | Pasteur Institut | Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel |
| GB0724051D0 (en) | 2007-12-08 | 2008-01-16 | Medical Res Council | Mutant proteins and methods for producing them |
| UY32038A (es) | 2008-08-08 | 2010-03-26 | Glaxo Wellcome Mfg Pte Ltd | Inmunoblobulinas anti-cd127 y sus usos |
| WO2010085643A1 (en) | 2009-01-22 | 2010-07-29 | University Of Miami | Targeting il-7 signaling as a therapy for multiple sclerosis and other il-7 signaling dependent disorders |
| AU2011209713B2 (en) | 2010-01-28 | 2014-04-03 | Glaxo Group Limited | CD127 binding proteins |
| AR080291A1 (es) | 2010-02-24 | 2012-03-28 | Rinat Neuroscience Corp | Anticuerpos antagonistas anti receptor de il-7 y procedimientos |
| EP2583980A1 (en) * | 2011-10-19 | 2013-04-24 | Effimune | Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates |
| US20150297310A1 (en) * | 2014-04-17 | 2015-10-22 | Georgia Regents Research Institute, Inc. | Methods for selecting a treatment for cancer |
| EP2955196A1 (en) * | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
-
2017
- 2017-02-28 LT LTEP17716593.3T patent/LT3423496T/lt unknown
- 2017-02-28 PL PL17716593T patent/PL3423496T3/pl unknown
- 2017-02-28 MD MDE20190066T patent/MD3423496T2/ro not_active IP Right Cessation
- 2017-02-28 AU AU2017225495A patent/AU2017225495B2/en active Active
- 2017-02-28 US US16/080,572 patent/US11230602B2/en active Active
- 2017-02-28 BR BR112018067479A patent/BR112018067479A2/pt unknown
- 2017-02-28 DK DK17716593.3T patent/DK3423496T3/da active
- 2017-02-28 KR KR1020187028377A patent/KR20180118746A/ko not_active Application Discontinuation
- 2017-02-28 ES ES17716593T patent/ES2737307T3/es active Active
- 2017-02-28 EP EP17716593.3A patent/EP3423496B1/en active Active
- 2017-02-28 PT PT17716593T patent/PT3423496T/pt unknown
- 2017-02-28 WO PCT/IB2017/000293 patent/WO2017149394A1/en active Application Filing
- 2017-02-28 JP JP2018545380A patent/JP7053479B2/ja active Active
- 2017-02-28 RS RSP20190987 patent/RS59223B1/sr unknown
- 2017-02-28 SI SI201730078T patent/SI3423496T1/sl unknown
- 2017-02-28 ME MEP-2019-215A patent/ME03446B/me unknown
- 2017-02-28 IL IL261330A patent/IL261330B2/en unknown
- 2017-02-28 MA MA43767A patent/MA43767B1/fr unknown
- 2017-02-28 HU HUE17716593A patent/HUE045183T2/hu unknown
- 2017-02-28 CA CA3014313A patent/CA3014313A1/en active Pending
- 2017-02-28 CN CN201780014099.2A patent/CN109195987B/zh active Active
-
2019
- 2019-08-09 HR HRP20191445 patent/HRP20191445T1/hr unknown
- 2019-08-23 CY CY20191100905T patent/CY1122072T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3423496A1 (en) | 2019-01-09 |
| MD3423496T2 (ro) | 2020-01-31 |
| HRP20191445T1 (hr) | 2019-11-15 |
| US11230602B2 (en) | 2022-01-25 |
| KR20180118746A (ko) | 2018-10-31 |
| EP3423496B1 (en) | 2019-07-03 |
| SI3423496T1 (sl) | 2019-10-30 |
| ES2737307T3 (es) | 2020-01-13 |
| PT3423496T (pt) | 2019-09-05 |
| CN109195987B (zh) | 2022-05-27 |
| RS59223B1 (sr) | 2019-10-31 |
| CA3014313A1 (en) | 2017-09-08 |
| US20200308288A1 (en) | 2020-10-01 |
| AU2017225495A1 (en) | 2018-08-23 |
| AU2017225495B2 (en) | 2024-05-09 |
| CY1122072T1 (el) | 2020-11-25 |
| WO2017149394A1 (en) | 2017-09-08 |
| JP7053479B2 (ja) | 2022-04-12 |
| HUE045183T2 (hu) | 2019-12-30 |
| IL261330B2 (en) | 2023-03-01 |
| MA43767A (fr) | 2019-01-09 |
| JP2019515648A (ja) | 2019-06-13 |
| LT3423496T (lt) | 2019-09-25 |
| IL261330B (en) | 2022-11-01 |
| ME03446B (me) | 2020-01-20 |
| MA43767B1 (fr) | 2019-08-30 |
| PL3423496T3 (pl) | 2020-01-31 |
| CN109195987A (zh) | 2019-01-11 |
| DK3423496T3 (da) | 2019-08-19 |
| IL261330A (en) | 2018-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018067479A2 (pt) | anticorpo, fragmento de ligação ao antígeno de um anticorpo, molécula quimérica, receptor de antígeno quimérico, polinucleotídeo, célula, métodos para preparação de receptor de antígeno quimérico, para fabricação de um anticorpo e para determinação da presença de células cd127+, composição farmacêutica, meio terapêutico de combinação, método de diagnóstico, e, uso de um anticorpo anti-cd127 ou um fragmento de ligação ao antígeno do mesmo | |
| SA517381703B1 (ar) | C10orf54 - أجسام مضادة لـ واستخداماتها | |
| CL2023000895A1 (es) | Receptores quiméricos de dll3 y métodos para su uso | |
| PE20180330A1 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 y metodos para su uso | |
| EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
| PH12018500216A1 (en) | Antibody constructs for cd70 and cd3 | |
| MX2021013336A (es) | Anticuerpos y receptores de antigeno quimericos especificos para cd19. | |
| MY184895A (en) | Antibody constructs for dll3 and cd3 | |
| BR112021021843A8 (pt) | Composições de proteínas de fusão quiméricas modificadas e método de uso das mesmas | |
| CL2011002417A1 (es) | Anticuerpo especifico para fcrh5, receptor de superficie celular con homologia con las familias del receptor fc; anticuerpo anti-fcrh5 humanizado; polinucleotido que lo codifica; vector; celular huesped; metodo de obtencion; inmunoconjugado; composicion farmaceutica; y su uso para tratar cancer. | |
| EA201792193A1 (ru) | Конструкции биспецифического антитела для cdh3 и cd3 | |
| MX2017001599A (es) | Anticuerpos novedosos y sus usos. | |
| WO2019014328A3 (en) | AGONISTIC ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF | |
| EA201991005A1 (ru) | Антитела и полипептиды, направленные против cd127 | |
| PH12016501366A1 (en) | Novel anti-baff antibodies | |
| AR103726A1 (es) | Cristales de anticuerpos monoclonales anti-pd-1 humanos | |
| MX2019015352A (es) | Linfocitos t con receptor de antigeno quimerico (car) para receptor 1 huerfano tipo receptor de tirosina cinasa (ror 1). | |
| MX2024005669A (es) | Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano. | |
| MX2017009680A (es) | Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d). | |
| MX2022007706A (es) | Anticuerpos utiles en diagnosis de cancer. | |
| EA202092085A1 (ru) | ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ | |
| SA518391028B1 (ar) | Cd37 أجسام مضادة واختبارات للكشف عن | |
| PH12019502694A1 (en) | Anti-trkb antibodies | |
| EA201992317A1 (ru) | Композиции и способы для диагностики рака легких | |
| BR112023020802A2 (pt) | Polipeptídeo de ligação a gucy2c e usos do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |